This assumption was based on the observations that strong AhR ligands degraded AR in the LNCaP prostate cell line [15,19] and that two other compounds, namely Icaritin [24] and Carbidopa [25], which could activate AhR, suppressed prostate cancer via AhR-mediated degradation of AR. The gene discussed is AHR; the disease is prostate carcinoma.